About ERIX
EiRx Therapeutics is a specialist provider of pre-clinical therapeutics to the pharmaceutical industry. Our unique scientific expertise and knowledge in the field of Apoptosis provide a sound base to discover and develop new medicines that will safely and selectively repair this natural process in disease. The potential benefits from these new medicines are enormous, since as many as 70% of all human disease have some defect in the control of Apoptosis.
Apoptosis - the biological process that determines whether cells in our bodies live or die...
http://www.eirx.com/index.html

Purchased some of these on the strength of the PROGRESS UPDATE looks promising.
http://moneyam.uk-wire.com/cgi-bin/articles/200603200701130254A.html

ERX interview with John Pool
http://www.wallstreetreporter.com/interview.php?id=18589&player=real
Latest News
CANCER COLLABORATION WITH BIOMERIEUX SA
http://moneyam.uk-wire.com/cgi-bin/articles/200607120700230534G.html
Biomerieux Web Site
http://www.biomerieux.com/servlet/srt/bio/portail/home
ABOUT ERX Focus Of The Month
http://www.billamag.net/focus-document-text.asp?FocusTextID=1
ERX pdf filehttp://www.eirx.com/eirx_heading_images/Yokohama2005.pdf
19/09/2006 A 50% reduction in breast tumour volume size seen with Eirx lead molecule in animal studies
http://moneyam.uk-wire.com/cgi-bin/articles/200609190700171175J.html

Past and present collaborative partners include:

* bioMieux SA
* Almac Diagnostics Ltd
* Merck & Co, Ltd
* Biofocus plc
* MGI Pharmaceuticals, Inc
* OSI Pharmaceuticals, Inc
* Sareum plc
* Regen Therapeutics plc
* SR Pharma plc

Explains the action today.

D/Express Artical today

Drug discovery company Eirx therapeutics, which is developing therapies for cancer and has just raised 1.2 million through a placing, eased 0.02p to 0.026p amid speculation a deal with a Danish company was imminent.

I don't know anything about Danish drug companies other than the company ZGene, which is developing cancer drugs - could be them, but have no idea really. That should not detract from the sp long term.
kim

sounds as though rewards are on the horizon-this is probably the reason the share placing hasn't knocked them more.

Lets not forget why we invested in ERX I topped up today.

EiRx passed an important milestone in August 2005 with the filing of the company's first patents covering distinct chemical compounds that may be useful in the treatment of cancer. These drug candidates were identified using the Company's EnPADTM screening technology, which enables the discovery of compounds that specifically target the cell survival pathways relied upon by tumours for continued growth and viability. In January of 2006, the Company announced a second patent application describing another series of compounds identified with the use of EnPADTM. Both these patent applications describe series of novel compounds that selectively kill colorectal and breast cancer cells in vitro.

With the benefit of the anticipated new funds I am confident that EiRx can progress to secure proof of concept for the leading compounds in our pipeline, creating a solid basis for future partnering activities.

This is one of my two blues today the rest are RED good old erx.

Renewed interest may be some news soon?

Hope so-just back from 2 weeks in Majorca-not much contact with the market so very glad to be out of the turmoil! glad to see erx and hml are holding up not so impressed with PCM without the bid tv deal how much of a business do they have?? not much I can salvage so will have to hold on-also a bit sick to have sold 30000 TTC shares before going away and missed out on the takeover when will I learn not to be hasty!!

mp
Hope you had a good time best place to be with the ftse in a dive pcm we will have to hold I'm afraid and see what happens.

Topped up today the sp could move very fast with some news that could appear at any time.

There could be strong news flow as three or four compounds move along the drug discovery cycle.
Large Pharma competition pushing licensing activity to earlier stages of development
Focus on cancer is lucrative in terms of both licensing deals and M&A activity.
Also big Pharma can look to acquire cancer companies for access to product pipeline.
Discussion with major pharmas can be convoluted and a number of such discussions to secure out licensing agreements are on going.

ERX interview just click on the link, also in the header.


http://www.wallstreetreporter.com/interview.php?id=18589&player=real

Thank you so much driver-what an exciting find.quite apart from holding the shares I very much hope the company has it's breakthrough soon. The Chairman sounded a sincere man quite a change these days!!

I can reinforce the message delivered by driver, the company are at a fairly advanced stage of negotiations with more than one option on the table. Coupled with this you should also expect to see a change of house broker

Nice one Driver! Confirms our opinion that the company is "extremely undervalued at the moment" Couldn't be happier to be in right now!
kim

A nice 18% rise this morning that's more like it.

PORTFOLIO REVIEW Last updated: 23/02/06

Billam AG have reviewed the Technical Portfolio of EiRx Therapeutics plc and detail it as follows:

ALIBI genomics discovery platform (2 patents, plus skills and know-how in genomics and cell biology)

Patents on 100+ potential drug targets in apoptosis and tumour cell survival pathways

OSI Pharmaceuticals license agreement milestones of up to $4.9M per target

siRNA technology liposomal delivery vector and panel of 60+ tumour cell lines in 15 phenotypic and functional assays

EnPAD technology skills and know-how in engineering cellular drug screening model

EnPAD -catenin cell line (+ EnPAD PI3K/Akt cell line in development Q1 06)

Pyrazolopyrimidine patent new family of potential drug compounds targeting catenin signalling

2-aminopyridine patent new family of potential drug compounds targeting -catenin signalling

Marie Curie grant programme approx. 400,000 left to draw down

Exclusive commercial license to Aberdeen Colorectal Tissue Bank

Colorectal cancer markers patent on 11 proteins from proteomic study

Cytochrome P450 1B1 intellectual property (3 patents covering diagnostic, therapeutic use)

MGI Pharma license agreement ($100,000 at Phase II, $250,000 at Phase III, $0.5M at NDA, 2% of net sales or 8.5% of sublicense income.

Cytochrome P450 patent 5 more proteins over-expressed in tumours

CYP51 inhibitor project

ArraDx collaboration - 200,000 to come from InterTrade Ireland INNOVA grant


http://www.billamag.net/focus-text-main-quoted.asp?FocusTextID=33

Nice bit of news today.

CANCER COLLABORATION WITH BIOMERIEUX SA


Cork, Ireland - EiRx Therapeutics plc (AIM: ERX), the drug discovery company
developing targeted therapies for cancer, is pleased to announce that it has
entered into a collaboration agreement with bioMerieux SA, the leading
international diagnostics group headquartered in Marcy l'Etoile, France. Under
the terms of the agreement, the companies will work together to validate the
diagnostic and therapeutic potential of candidate tumour markers emerging from
their respective cancer research programmes.

http://moneyam.uk-wire.com/cgi-bin/articles/200607120700230534G.html

BioMieux is present in over 130 countries, with more than 100 distributors and 33 subsidiaries, and continues its international development.


Biomerieux Web Site is in the header.

300k+ trade gone through thats large in my book. Up 37% looking good.

excellent news but revenues still seem a long way off!

mp
Never mind the revenues the deal they done with this company is huge for such a tiddler as erx we can see this going to 1p and beyond in the next week or so.